What are Clinical Trials and why do we need them?
Clinical trials are carefully designed research studies conducted in humans to evaluate the safety, efficacy, and overall benefit of medical interventions such as drugs, biologics, or devices. They progress through phases 1 to 4, each with distinct goals, methods, and regulatory requirements. Below is a full explanation of each phase: 🔬 Preclinical Studies (Before Phase […]
What is “Enforcement Discretion” (FDA context)?
Enforcement discretion means that a regulatory agency like the FDA (U.S. Food and Drug Administration) chooses not to enforce certain rules or regulations under specific circumstances, even if technically a violation has occurred. This is often done:• To avoid disrupting access to critical healthcare (e.g., during emergencies like COVID-19).• When the agency believes that the […]
Retatrutide: A Triple Agonist for Diabetes and Obesity
Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. The power of three: Retatrutide’s role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024 Dec 15;985:177095. doi: 10.1016/j.ejphar.2024.177095. Epub 2024 Nov 6. PMID: 39515565. Comprehensive narrative review focusing on retatrutide, […]
GLP-1 Agonists and Neurological Adverse Events in FAERS
Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. Sci Rep. 2025 May 24;15(1):18063. doi: 10.1038/s41598-025-01206-9. PMID: 40413246; PMCID: PMC12103604. This research utilizes data from […]
Camurus: Advancing Patient Care Through Innovation with FluidCrystal®
Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are formulated and administered to achieve optimal therapeutic effect. These drugs are primarily used in type 2 diabetes and obesity treatment. 🧬 What Are Incretins?Incretins are hormones released by the gut […]
The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan Paperback – June 3, 2025
by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds uncovers the cellular mechanisms behind GLP-1s and other peptides that can help people lose significant weight and treat type-2 diabetes. Importantly, Dr. Seeds has also gathered peer-reviewed research that shows […]
Nourishing GLP-1 Therapy for Obesity
This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor agonists (GLP-1s) for obesity treatment, highlighting their efficacy in weight reduction and other clinical benefits while also addressing significant challenges like gastrointestinal side effects, potential nutrient deficiencies, and loss of muscle and bone mass. The authors […]
MAHA Agenda Excludes GLP-1 Coverage Expansion
PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo Nordisk. Although a Biden-era proposal to expand coverage was rejected due to concerns about the high cost to the federal government, […]
The Ozempic Era and Shifting Obesity Blame
Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41, no. 3 (Spring 2025): 24–26. https://doi.org/10.58875/TEQC7966 Laura A. Schmidt is a professor of health policy in the School of Medicine at the University of California, San Francisco. Luc L. Hagenaars is assistant professor […]
Is Obesity Genetic or Environmental? YES!
Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific disease or trait. It involves comparing the genomes of individuals with the disease or trait to those without it to find variations that occur more frequently in the affected group. SNP […]